Oral delivery of Trichinella spiralis antigens by yeast-derived β-glucan particles enhances anti-helminth immunity

  • NPJ Vaccines. 2026 May 5;11(1):143. doi: 10.1038/s41541-026-01458-0.
Zhina Liu  #  1 Yi Liu  #  1 Zijian Dong  #  1 Yaming Yang  2 Longjiang Tian  3 Xingyang Wang  1 Zhiyang Du  3 Xiaolei Liu  1 Xue Bai  1 Xuemin Jin  4
Affiliations
  • 1. State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Key Laboratory for Zoonosis Research of Ministry of Education, Institute of Zoonosis, and College of Veterinary Medicine, Jilin University, Changchun, China.
  • 2. Department of Helminth, Yunnan Institute of Parasitic Diseases, Puer, China.
  • 3. Jilin Provincial Key Laboratory of Nutrition and Functional Food, College of Food Science and Engineering, Jilin University, Changchun, China.
  • 4. State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Key Laboratory for Zoonosis Research of Ministry of Education, Institute of Zoonosis, and College of Veterinary Medicine, Jilin University, Changchun, China. [email protected].
  • # Contributed equally.
Abstract

Intestinal helminth infections including Trichinella spiralis impose a heavy burden globally, yet effective oral vaccines are lacking due to antigen degradation and poor mucosal immunogenicity. This study develops an oral vaccine platform using yeast-derived β-glucan particles (GPs) to encapsulate T. spiralis antigens (Ag-GPs). These Ag-GPs demonstrated efficient antigen encapsulation, gastrointestinal stability, and excellent biocompatibility. In a mouse model, oral immunization with Ag-GPs was biocompatible and induced robust mucosal (SIgA) and systemic (IgG, IgE) antibody responses, while also stimulating dendritic cell maturation and T-cell activation. This immunization resulted in significant reductions in both adult worm and muscle larval burdens following T. spiralis challenge. Notably, the observed protective immunity strongly correlated with Dectin-1 receptor-mediated particle uptake and subsequent systemic immune activation. This work presents a promising dual-function platform, acting as both an Adjuvant and delivery system, for developing oral vaccines against intestinal parasites.

Products
Inhibitors & Agonists
Other Products